Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model.

Van Bocxlaer, K; Yardley, V; Murdan, S; Croft, SL; (2016) Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model. The Journal of pharmacy and pharmacology, 68 (7). pp. 862-72. ISSN 0022-3573 DOI:

Text - Accepted Version

Download (544kB) | Preview


UNLABELLED: Cutaneous leishmaniasis (CL) is caused by several species of the protozoan parasite Leishmania and affects approximately 10 million people worldwide. Currently available drugs are not ideal due to high cost, toxicity, parenteral administration and suboptimal efficacy. Miltefosine is the only oral treatment (Impavido®) available to treat CL, given over a period of 28 days with common side effects such as vomiting and diarrhoea.<br/> OBJECTIVE: To explore the local application of miltefosine as a topical formulation to enhance activity and reduce the drug's adverse effects.<br/> METHODS: The antileishmanial activity of miltefosine was confirmed in vitro against several Leishmania species. The permeation of miltefosine, in different solvents and solvent combinations, through BALB/c mouse skin was evaluated in vitro using Franz diffusion cells. The topical formulations which enabled the highest drug permeation or skin disposition were tested in vivo in BALB/c mice infected with L. major.<br/> KEY FINDINGS: The overall permeation of miltefosine through skin was low regardless of the solvents used. This was reflected in limited antileishmanial activity of the drug formulations when applied topically in vivo. All topical formulations caused skin irritation.<br/> CONCLUSIONS: We conclude that miltefosine is not an appropriate candidate for the topical treatment of CL.<br/>

Item Type: Article
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Immunology and Infection
Research Centre: Leishmaniasis Group
Neglected Tropical Diseases Network
PubMed ID: 27230300
Web of Science ID: 379942000002


Download activity - last 12 months
Downloads since deposit
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item